Literatur
-
01
Kovesdy C P, Ahmadzadeh S , Anderson J E, Kalantar-Zadeh K .
Association of activated vitamin D treatment and mortality in chronic kidney disease.
Arch Intern Med.
2008;
168
397-403
-
02
Shinaberger C S, Kopple J D, Kovesdy C P, et al .
Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients.
Clin J Am Soc Nephrol.
2008;
3
1769-1776
-
03
Regidor D L, Kovesdy C P, Mehrotra R , et al .
Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients.
J Am Soc Nephrol.
2008;
19
2193-2203
-
04
Shantouf F , Kovesdy C P, Kim Y , et al .
Association of serum alkaline phosphatase with coronary artery calcification in maintenance hemodialysis patients.
Clin J Am Soc Nephrol.
2009;
4
1106-1114
-
05
Kalantar-Zadeh K , Kovesdy C P.
Clinical outcomes with active versus nutritional vitamin D compounds in chronic kidney disease.
Clin J Am Soc Nephrol.
2009;
4
1529-1539
-
06
Dukkipati R , Kalantar-Zadeh K , Kopple J D.
Is there a role for intradialytic parenteral nutrition? A review of the evidence.
Am J Kidney Dis.
2010;
55
352-364
-
07
Teng M , Wolf M , Lowrie E , et al .
Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy.
N Eng J Med.
2003;
349
446-456
-
08
Teng M , Wolf M , Ofshun M N, et al .
Activated injectable vitamin D and hemodialysis survival: a historical cohort study.
J Am Soc Nephrol.
2005;
16
1115-1125
-
09
Lund R J, Andress D L, Amdahl M , et al .
Absorption in Hemodialysis Patients.
Am J Nephrol.
2010;
31
165-170
-
10
Mizobuchi M , Finch J L, Martin D R, et al .
Differential effects of vitamin D receptor activators on vascular calcification in uremic rats.
Kidney Int.
2007;
72
709-715
-
11
Wu-Wong J R, Noonan W , Ma J , et al .
Role of phosphorus and vitamin D analogs in the pathogenesis of vascular calcification.
J Pharmacol Exp Ther.
2006;
318
90-98
-
12
Henley C , Colloton M , Cattley R C, et al .
1,25-Dihydroxyvitamin D3 but not cinacalcet HCl treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism.
Nephrol Dial Transplant.
2005;
20
1370-1377
-
13
Agarwal R , Acharya M , Tian J , et al .
Antiproteinuric effect of oral paricalcitol in chronic kidney disease.
Kidney Int.
2005;
68
2823-2828
-
14
Alborzi P , Patel N A, Peterson C , et al .
Paricalcitol reduces albuminuria and inflammation in chronic kidney disease. A randomized double-blind pilot trial.
Hypertension.
2008;
52
249-255
-
15 de Zeeuw D , Agarwal R , Parving H , et al . A study of paricalcitol capsules on reducing albuminuria in type 2 diabetic nephropathy being treated with renin-angiotensin system inhibitors (NCT00421733). Im Internet:. http://www.clinicaltrials.gov 08.03.2010
01 Selective Vitamin D Receptor (VDR) Activator for Albuminuria Lowering (VITAL) Study in Type 2 Diabetic Nephropathy
